Evaluating maturation and genetic modification of human dendritic cells in a new polyolefin cell culture bag system

Transfusion

Volumn 50, Issue 4, 2010, Pages 843-855

  MacKe, Lars ^a,b,c   Garritsen, Henk S P ^a,b,c   Meyring, Wilhelm ^a,b,c   Hannig, Horst ^a,b,c   Pägelow, Ute ^a,b,c   Wörmann, Bernhard ^a,b,c   Piechaczek, Christoph ^a,b,c   Geffers, Robert ^a,b,c   Rohde, Manfred ^a,b,c   Lindenmaier, Werner ^a,b,c   Dittmar, Kurt E J ^a,b,c  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c Miltenyi Biotec   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; INTERLEUKIN 4; MEMBRANE ANTIGEN; POLYOLEFIN;

ADENOVIRUS; ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; CD14+ CELL; CELL CULTURE; CELL CULTURE EQUIPMENT; CELL MATURATION; CELL POPULATION; CELL SELECTION; CHILD; COLONY FORMING UNIT GM; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; DNA MODIFICATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; MONOCYTE; MONONUCLEAR CELL; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SAFETY; SCHOOL CHILD;

ADULT; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, SURFACE; CELL AGING; CELL COUNT; CELL CULTURE TECHNIQUES; CELL DIVISION; CHILD; DENDRITIC CELLS; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; LEUKAPHERESIS; LEUKOCYTES; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 77950233832     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02520.x     Document Type: Article

References (48)

1. De Bari C, Dell'Accio F. Cell therapy: a challenge in modern medicine. Biomed Mater Eng 2008 18 : S11 7.
2. Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996 87 : 3082 8.
3. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007 220 : 129 50.
4. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008 41 : 99 108.
5. Dauer M, Schnurr M, Eigler A. Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines 2008 7 : 1041 53.
6. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009 58 : 1 14.
7. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004 10 : 1359 65.
8. O'Neill HC. Dendritic cell therapy for tolerance induction to stem cell transplants. Curr Stem Cell Res Ther 2006 1 : 121 5.
9. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007 449 : 419 26.
10. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002 268 : 131 40.
11. Campbell-Anson RE, Kentor D, Wang YJ, Bushnell KM, Li Y, Vence LM, Radvanyi LG. A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. J Immune Based Ther Vaccines 2008 6 : 1.
12. Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology 2005 114 : 204 12.
13. Pullarkat V, Lau R, Lee SM, Bender JG, Weber JS. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002 267 : 173 83.
14. Strasser EF, Dittrich S, Weisbach V, Zimmermann R, Ringwald J, Achenbach S, Zingsem J, Eckstein R. Comparison of two mononuclear cell program settings on two apheresis devices intended to collect high yields of CD14+ and CD3+ cells. Transfusion 2004 44 : 1104 11.
15. Becker C, Pohla H, Frankenberger B, Schüler T, Assenmacher M, Schendel DJ, Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001 7 : 1159 62.
16. Campbell JD, Piechaczek C, Winkels G, Schwamborn E, Micheli D, Hennemann S, Schmitz J. Isolation and generation of clinical-grade dendritic cells using the CliniMACS system. Methods Mol Med 2005 109 : 55 70.
17. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007 30 : 663 74.
18. de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002 25 : 429 38.
19. Mu LJ, Lazarova P, Gaudernack G, Saeboe-Larssen S, Kvalheim G. Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells. Int J Immunopathol Pharmacol 2004 17 : 255 63.
20. Buchler T, Kovarova L, Musilova R, Bourkova L, Ocadlikova D, Bulikova A, Hanak L, Michalek J, Hajek R. Generation of dendritic cells using cell culture bags - description of a method and review of literature. Hematology 2004 9 : 199 205.
21. Gulen D, Abe F, Maas S, Reed E, Cowan K, Pirruccello S, Wisecarver J, Warkentin P, Northam M, Turken O, Coskun U, Senesac J, Talmadge JE. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol 2008 8 : 1728 36.
22. Janssen W. Data management in the cell therapy production facility: the batch process record (BPR). Cytotherapy 2008 10 : 227 37.
23. Nicolette CA, Healey D, Tcherepanova I, Whelton P, Monesmith T, Coombs L, Finke LH, Whiteside T, Miesowicz F. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007 25 Suppl 2 : B47 60. Epub 2007 Jun 21:B47-60.
24. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kämpgen E, Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999 223 : 1 15.
25. Garritsen HSP, Macke L, Meyring W, Hannig H, Pägelow U, Wörmann B, Geffers R, Dittmar KEJ, Lindenmaier W. Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins. Transfusion 2010 50 : 831 42.
26. Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol 2003 58 : 578 86.
27. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 2008 222 : 256 76.
28. O'Neill DW, Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Mol Biotechnol 2007 36 : 131 41.
29. Lesterhuis WJ, Aarntzen EH, de Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008 66 : 118 34.
30. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 10 : 909 15.
31. Guyre CA, Fisher JL, Waugh MG, Wallace PK, Tretter CG, Ernstoff MS, Barth RJ Jr. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods 2002 262 : 85 94.
32. Rouard H, Leon A, Klonjkowski B, Marquet J, Tennezé L, Plonquet A, Agrawal SG, Abastado JP, Eloit M, Farcet JP, Delfau-Larue MH. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods 2000 241 : 69 81.
33. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002 264 : 135 51.
34. Macke L, Wrobel B, Meyring W, Garritsen H, Woermann B, Rohde M, Lindenmaier W, Dittmar KE. Comparison of flask and bag systems in cultivation of dendritic cells for clinical application. Proceedings of the 19th ESACT Meeting: Cell Technology Processes for Cell Products, Harrogate, UK. Springer Verlag 2005.
35. Putz T, Gander H, Ramoner R, Zelle-Rieser C, Rahm A, Nussbaumer W, Bartsch G, Höltl L, Thurnher M. Generation of clinical-grade monocyte-derived dendritic cells using the CliniMACS system. Methods Mol Med 2005 109 : 71 82.
36. Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001 166 : 3678 87.
37. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001 22 : 102 7.
38. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999 29 : 964 72.
39. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008 31 : 294 309.
40. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000 191 : 1699 708.
41. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003 170 : 2912 22.
42. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappaB (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J Immunol 2003 171 : 4121 30.
43. Kurlander RJ, Tawab A, Fan Y, Carter CS, Read EJ. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. Transfusion 2006 46 : 1494 504.
44. Lopez JA, Bioley G, Turtle CJ, Pinzón-Charry A, Ho CS, Vuckovic S, Crosbie G, Gilleece M, Jackson DC, Munster D, Hart DN. Single step enrichment of blood dendritic cells by positive immunoselection. J Immunol Methods 2003 274 : 47 61.
45. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997 27 : 3135 42.
46. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, Geiger JD, Hanash S, Beretta L. Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J Biol Chem 2001 276 : 17920 31.
47. Messmer D, Messmer B, Chiorazzi N. The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells. Int Immunol 2003 15 : 491 503.
48. Tureci O, Bian H, Nestle FO, Raddrizzani L, Rosinski JA, Tassis A, Hilton H, Walstead M, Sahin U, Hammer J. Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J 2003 17 : 836 47.